Immune thrombocytopenia (ITP) is diagnosed primarily by exclusion, meaning there is no single test that confirms it. Instead, doctors look for a platelet count below 100,000 per microliter of blood, confirm that other blood cell counts are normal, and systematically rule out every other condition that could explain the low platelets. The process combines blood tests, a physical exam, and sometimes additional screening depending on age and symptoms.
What Doctors Look for First
The starting point is a complete blood count, or CBC. In ITP, platelets are low while white blood cells and hemoglobin remain normal. That combination is key. If all three cell lines are abnormal, something else is going on, and the diagnostic path shifts toward bone marrow disorders or other systemic conditions.
A physical exam focuses on visible signs of bleeding. Petechiae, which are tiny flat red dots on the skin caused by blood leaking from small vessels, are a hallmark finding. Larger patches of discoloration under the skin (purpura) that appear red, purple, or brownish-yellow are also common. Other signs include nosebleeds, bleeding gums, blood in urine or stool, unusually heavy menstrual periods, and lumps under the skin where blood has partially clotted. Some people also experience fatigue, pale skin, and dizziness if the bleeding has been enough to cause anemia.
The Peripheral Blood Smear
One of the first follow-up steps is examining a blood sample under a microscope. This serves two purposes. First, it rules out pseudothrombocytopenia, a lab artifact where platelets clump together in the collection tube and make the count appear falsely low. Platelet clumps visible on the slide mean the machine simply miscounted, and the patient’s platelets may actually be fine.
Second, the smear lets a pathologist look at the shape and maturity of all blood cells. In ITP, the cells should look normal with no signs of dysplasia, which refers to irregular shapes or sizes that suggest a bone marrow problem like myelodysplastic syndrome or leukemia. If immature white blood cells appear on the smear, or if neutrophils and lymphocytes are present in unusual ratios, the diagnosis shifts away from ITP and toward something more serious that requires bone marrow testing.
Screening for Secondary Causes
Not all ITP is the same. Primary ITP means the immune system is attacking platelets for no identifiable reason. Secondary ITP means something else, like an infection or autoimmune disease, is triggering the platelet destruction. The treatment and outlook differ significantly between the two, so distinguishing them matters.
Guidelines recommend testing all adults with suspected ITP for HIV, hepatitis B, and hepatitis C regardless of personal risk factors or how common these infections are locally. In some cases, treating the underlying infection leads to a complete recovery of platelet counts without any ITP-specific therapy. Testing for Helicobacter pylori, the stomach bacterium linked to ulcers, is also typically part of the initial workup.
Depending on the clinical picture, doctors may also screen for autoimmune conditions like lupus, since ITP can be the first sign of a broader autoimmune process. Adults with ITP are more likely than children to have at least one coexisting condition. Registry data show that over 30% of adults have a comorbidity at presentation, compared to fewer than 4% of children.
When a Bone Marrow Biopsy Is Needed
Most people with suspected ITP do not need a bone marrow biopsy. Guidelines reserve it for situations where the diagnosis is uncertain or where the risk of a masquerading condition is higher. The clearest trigger is age: patients over 60 are more likely to have myelodysplastic syndrome, a bone marrow disorder that can mimic ITP by causing isolated low platelets. For this group, a bone marrow aspirate is considered informative and often recommended.
Regardless of age, a biopsy is strongly recommended if the blood smear shows certain red flags: a white blood cell count below 3,000 or above 10,000, a high mean cell volume (MCV above 110, suggesting abnormally large red blood cells), the presence of immature white blood cells, or an unusual ratio of neutrophils to lymphocytes. Cases where ITP doesn’t respond to standard treatment also prompt bone marrow examination to make sure the original diagnosis was correct. Research has found that roughly one-third of patients ultimately diagnosed with myelodysplastic syndrome were under 60 and had low platelets as their only abnormality, which is why some experts advocate for a lower threshold for biopsy than current guidelines suggest.
Why There’s No Definitive ITP Test
You might expect a test that detects the antibodies attacking your platelets to settle the diagnosis. Such a test exists, but it has a significant limitation. A systematic review and meta-analysis found that direct anti-platelet antibody testing has a sensitivity of only 53%, meaning it misses nearly half of people who actually have ITP. Its specificity, however, is 93%, so a positive result is strong evidence in favor of ITP. Indirect antibody testing performs even worse on sensitivity, catching only about 18% of cases.
In practical terms, a positive antibody test can help confirm ITP when the diagnosis is in question, but a negative result is essentially meaningless. It cannot be used to rule out the condition. This is why ITP remains a diagnosis of exclusion rather than a diagnosis confirmed by a specific lab marker.
How Diagnosis Differs in Children
ITP in children tends to look different from the adult version in ways that affect the diagnostic approach. Childhood ITP is more often acute and self-limited. Data from an international registry of nearly 1,500 children showed that 69% achieved complete remission within six months without aggressive treatment. The condition affects boys and girls roughly equally in childhood, while adult ITP skews toward women at about a 2:1 ratio.
Children with ITP actually bleed more frequently than adults at diagnosis. In one prospective cohort, 91% of children had bleeding symptoms compared to 69% of adults. Despite this, the most dangerous complication, intracranial hemorrhage, is rarer in children (about 0.5%) than in adults (about 1.5%), with risk climbing further after age 60. Because childhood ITP is more predictable and less likely to be secondary, recent guideline trends have moved away from exhaustive testing in children who present with a typical picture. For a child with isolated low platelets, a normal blood smear, and no unusual findings on exam, the workup can be relatively straightforward.
ITP Categories After Diagnosis
Once confirmed, ITP is classified by how long it persists. The first three months after diagnosis are considered the “newly diagnosed” phase. If low platelet counts continue from 3 to 12 months, the condition is labeled persistent ITP. Beyond 12 months, it becomes chronic ITP. These distinctions guide treatment decisions. Many cases of newly diagnosed ITP, particularly in children, resolve on their own. Chronic ITP, more common in adults, typically requires ongoing management and closer monitoring to prevent bleeding complications.
The 2019 American Society of Hematology guidelines remain the current standard for diagnosis and management. A 2024 review found that while new evidence has emerged since then, it wasn’t enough to justify a full guideline revision. All prior recommendations remain relevant, with minor clarifications around second-line therapies in adults.